The best outcome after chemotherapy for Hodgkin’s lymphoma is an evaluation of the disease as a complete remission with no new lesions on follow-up examinations thereafter. The evaluation of the efficacy of chemotherapy in patients with Hodgkin’s lymphoma is categorized as complete remission (CR), partial remission (PR), stable disease (SD), and recurrent or progressive disease (PD). One of the best efficacy evaluations is CR, which is the disappearance of all evidence of disease with the following manifestations, including PET-CT results, clinical signs, and bone marrow biopsy: 1. PET-CT suggests that FDG (glucose uptake) activity has decreased to normal levels and enlarged lymph nodes, etc. have returned to normal size. 2. Liver and spleen are not enlarged and nodules disappear. 3. Bone marrow repeat biopsy suggested that tumor infiltration disappeared. Hodgkin patients are followed up every 3-6 months for 1-2 years after the end of treatment, every 6-12 months in the third year, and once a year thereafter. The evaluation of the efficacy of the disease and the time of follow-up should be judged by the patient’s supervising doctor or hematologist according to the actual situation of the patient.